SPRO earnings: next report 2026-08-11, real EPS beat/miss history, analyst consensus Buy, P/E 4.71. Updated 2026-07-23.
Spero Therapeutics (SPRO) Research Hub
Spero Therapeutics (SPRO) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 1.13 USD (-3.42%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 4.71, market cap 0.08B. This hub links to the full technical, earnings and options research available for SPRO.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.13 USD (-3.42%) |
| 52-week range | 1.08 USD – 3.05 USD |
| Trend regime | Range |
| 14-day RSI | 27.6 (Oversold) |
| Trailing P/E | 4.71 |
| Market cap | 0.08B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-11 |
Available research for SPRO
Covered Call on SPRO: how it works, illustrative setup around the real 1.13 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on SPRO: how it works, illustrative setup around the real 1.13 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on SPRO: how it works, illustrative setup around the real 1.13 USD price, max profit/loss, breakeven and when to use it. Educational.
SPRO technical analysis: range, last 1.13 USD, RSI 27.6, 52w range 1.08 USD–3.05 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is SPRO in?
Spero Therapeutics (SPRO) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is SPRO in an uptrend or downtrend?
As of 2026-09-11, SPRO is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is SPRO's trailing P/E ratio?
SPRO's trailing P/E is 4.71, with a market cap of 0.08B. See the earnings research page for full valuation detail.
When does SPRO next report earnings?
SPRO is next scheduled to report earnings on 2026-08-11, with a consensus EPS estimate of -0.17 USD.